Despite the complications associated with the administration of NHE1 inhibitors, delineating the molecular mechanisms downstream of NHE1 activation in the setting of CH is necessary to develop specific strategies to indirectly inhibit NHE1. Here, SLC9A1 is linked to cyclic hematopoiesis.